Avalo Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2019 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Avalo Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2019 to Q3 2024.
  • Avalo Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending September 30, 2024 was $1.14M, a 18.2% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 $1.14M -$254K -18.2% Sep 30, 2024 10-Q 2024-11-07
Q2 2024 $1.21M -$246K -16.9% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $1.28M -$402K -23.9% Mar 31, 2024 10-Q/A 2024-07-11
Q4 2023 $1.33M -$421K -24.1% Dec 31, 2023 10-Q 2024-11-07
Q3 2023 $1.39M -$420K -23.2% Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $1.46M -$420K -22.4% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $1.68M -$258K -13.3% Mar 31, 2023 10-Q 2023-05-04
Q4 2022 $1.75M -$251K -12.5% Dec 31, 2022 10-K 2024-03-29
Q3 2022 $1.81M +$1.12M +160% Sep 30, 2022 10-Q 2022-11-07
Q2 2022 $1.88M +$1.1M +143% Jun 30, 2022 10-Q 2022-08-04
Q1 2022 $1.94M +$1.09M +129% Mar 31, 2022 10-Q 2022-05-05
Q4 2021 $2M +$1.08M +118% Dec 31, 2021 10-K 2023-03-29
Q3 2021 $698K -$285K -29% Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $773K -$283K -26.8% Jun 30, 2021 10-Q 2021-08-02
Q1 2021 $846K +$136K +19.1% Mar 31, 2021 10-Q 2021-05-13
Q4 2020 $918K +$199K +27.7% Dec 31, 2020 10-K 2022-03-02
Q3 2020 $983K +$264K +36.8% Sep 30, 2020 10-Q 2020-11-09
Q2 2020 $1.06M +$328K +45.1% Jun 30, 2020 10-Q 2020-08-06
Q1 2020 $710K -$27.4K -3.72% Mar 31, 2020 10-Q 2020-05-07
Q4 2019 $719K Dec 31, 2019 10-K 2021-03-08
Q3 2019 $719K Sep 30, 2019 10-Q 2019-11-14
Q2 2019 $728K Jun 30, 2019 10-Q 2019-08-08
Q1 2019 $738K Mar 31, 2019 10-Q 2019-05-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.